LETTERS

Effect of Different Pharmacological Formulations of Gliclazide on Postprandial Hyperglycaemia

The pharmaceutical preparation of sulphonylurea tablets can affect their pharmacokinetics.[1] It has been recently reported that two different formulations of gliclazide may have a different dissolution kinetics.[2] We have compared two formulations: formulation A (Diamicron™, Laboratories Servier, Gidy, France) containing gliclazide 80 mg, lactose 66.3 mg, polyvinilpyrolidone (PVP) 8 mg, glyceril-behenate 5 mg, magnesium stearate 0.4 mg, colloidal silex 0.3 mg; formulation B (Diabrezide™, Molteni Farmaceutici, Florence, Italy) containing gliclazide 80 mg, lactose 33 mg, microcrystallin cellulose 20 mg, PVP 16 mg, sodium amylum glycolate 8 mg, magnesium stearate 3 mg.

The study was performed on eight volunteers (6 males, 2 females), with Type 2 diabetes mellitus, aged (mean ± SD) 58.7 ± 9.3 years, duration of diabetes of 7.4 ± 7.6 years, HbA_{1c} 6.0 ± 1.2 %, and body mass index 29.9 ± 4.9 kg m^{-2}, who had not received any pharmacological treatment in the previous 4 weeks. All participants gave their informed consent prior to the beginning of the study.

On the first day of the study, at 8.00 am, after overnight fast, two samples of venous blood were drawn at an interval of 15 min, to evaluate fasting glucose, insulin, and serum C-peptide levels; the means of the two measurements were used as baselines. Patients then randomly received formulation A or B. The patient was unaware of the treatment assigned, which was known to the physician. Ten minutes later, patients ate 25 g of white bread, together with coffee, and 50 g of skimmed milk and artificial sweetener (Aspartame) to taste. Blood was sampled at 60, 120, and 240 min. Patients were re-studied on the alternate formulation 7 days later and after a further 7 days, without any pharmacological treatment. Serum insulin was measured with an immunoassay (Boehringer Mannheim, Tutzing, Germany); serum C-peptide was evaluated through radioimmunoassay (Biodata Diagnostics, Rome, Italy).

Baseline plasma glucose (see Figure 1) was not significantly different prior to the three treatments. The AUC of plasma glucose was 32.7 ± 7.2 mmol l^{-1}/2h with formulation A, 26.4 ± 6.9 with formulation B, and 34.1 ± 8.7 in control ($p < 0.05$ by ANOVA). The glucose AUC after formulation B was significantly lower than with formulation A or control ($p < 0.05$ at paired Student's *t*-test), there were no significant differences between formulation A and control. No significant differences between the three treatments were observed in AUC of insulin and C-peptide (data not shown).



Figure 1. Glycaemic profile (mean ± SD) after formulation A (grey bars), formulation B (black bars), and in control conditions (white bars); *$p < 0.01$

Previous reports show that formulations of gliclazide containing glyceril-behenate may have a slow dissolution pattern *in vitro* at pH 7.4 and 1.2; while formulations containing sodium amylum glycolate seemed to show more rapid dissolution in aqueous solutions.[2] Such kinetic differences might lead to a difference in the bioavailability, and therefore in efficacy, of different formulations of gliclazide. Indeed, in controlled conditions, such as those of the present study, formulation B (containing sodium amylum glycolate) does appear to induce a greater reduction of postprandial blood glucose levels than formulation A (which contains glyceril-behenate). This might affect control of early postprandial hyperglycaemia.

This is the first study of *in vivo* pharmacokinetics of two formulations of gliclazide and further pharmacokinetics studies, especially *in vivo* studies on drug bioavailaility, are urgently needed. It should be noted that a difference in the acute effects on postprandial hyperglycaemia in controlled conditions does not necessarily imply that a similar difference can be observed on long-term metabolic control; this should be assessed through medium-term controlled trials.

G. Bardini, E. Mannucci, C.M. Rotella
Section of Metabolic Diseases and Diabetology, Division of Endocrinology, Department of Clinical Pathophysiology, University of Florence, Italy

References

1. Blume H, Ali SL, Stenzhorn G, Stuber W, Siewert M. Zur Bioverfugbarkeit und pharmakodynamischen Aktivitat handelsublicher Glibenclamid-Fertigarzneimittel; Mitteilung. *Pharm Ztg* 1985; **130**: 2605–2610.
2. Rodriguez L, Cavallari C, Cini M, Toffolo R. Dissoluzione *in vitro* della gliclazide da alcune forme solide a pronto rilascio. Influenza della formulazione e della tecnologia produttiva. In: *Atti del Simposio AFI-ISPE 1997, Montecatini Terme.* Montecatini Therme: AFI, 1997: 60.

Right Lateral Position Reduces Intra-individual Variation during Oral Glucose Tolerance Tests

A rise in plasma glucose levels after glucose ingestion correlates with gastric emptying rate (GER).[1,2] In the oral glucose tolerance test (OGTT), the time–concentration profile during the first 30 min greatly depends on GER, and that during the later phase primarily represents the effect of insulin.[3] This suggests that OGTTs will become a more direct reflection of glucose intolerance if an intra-individual variability in GER during the first 30 min can be minimized. A previous study has shown that a consistent acceleration of GER by a prokinetic drug makes OGTTs reproducible, probably because of the reduction in intra-individual variation in GER.[4] A simpler manoeuvre for enhancing GER is to place the subject in the right lateral decubitus position, in which the pylorus is at the 'bottom' of the stomach.[5] We investigated the influence of the right

 CCC 0742–3071/98/080706–03$17.50